Four FDA-approved anti-CGRP antibodies for migraine likely work by targeting peripheral nerve signaling rather than crossing into the brain.
4 approved drugstarget CGRP or its receptor peripherally, avoiding the need to cross the blood-brain barrier
What the researchers found
The review analyzes evidence on four FDA-approved anti-CGRP monoclonal antibodies: erenumab, fremanezumab, galcanezumab, and eptinezumab. All target either CGRP itself or its receptor in the trigeminovascular system.
The central question is whether these antibodies work inside the brain or outside it. At roughly 150 kDa (150,000 daltons), these molecules are far too large to cross an intact blood-brain barrier (BBB). Multiple studies confirm minimal BBB penetration.
The evidence points to peripheral mechanisms: the antibodies likely block CGRP signaling at sensory nerve endings in the meninges (brain coverings), at the trigeminal ganglion (a nerve cluster outside the BBB), and in peripheral blood vessels. Some researchers have suggested the antibodies might access areas where the BBB is leaky, such as the area postrema, but this remains debated.
Why it matters
Understanding where these drugs work matters for developing better versions. If peripheral action is sufficient, future migraine drugs do not need to cross the blood-brain barrier at all. This simplifies drug design and may reduce side effects. It also helps explain why these antibodies have remarkably clean safety profiles compared to older migraine drugs that act centrally.
The numbers in context
4 FDA-approved mAbs; ~150 kDa molecular weight; gepant development interrupted by pharmacokinetic issues
How the study worked
This is a narrative review summarizing published research on the pharmacology, pharmacokinetics, and mechanisms of action of anti-CGRP monoclonal antibodies. It draws from randomized clinical trials, preclinical animal studies, and pharmacokinetic analyses.
Who was studied
Review article (no direct study population)
What this study cannot tell us
As a narrative review, this paper selects and interprets existing evidence rather than generating new data. The question of BBB penetration is not fully settled; some evidence suggests partial BBB disruption during migraine attacks could allow limited antibody access. The review also cannot address long-term effects of blocking peripheral CGRP signaling.
How to read the evidence
Strong evidence. Based on clinical trial results and pharmacokinetic data from multiple FDA-approved drugs, synthesized in a comprehensive narrative review.
When this study was published
Published in 2020. The anti-CGRP drug class has expanded since, with additional oral CGRP antagonists (gepants) now available.
The bigger picture
Understanding that peripheral CGRP blockade is sufficient for migraine prevention simplifies future drug development. Designers do not need to engineer molecules that cross the blood-brain barrier, opening the door to safer, more accessible migraine treatments.
Questions still open
- Could partial BBB penetration contribute to efficacy in some patients?
- Why do some migraine patients not respond to anti-CGRP therapy?
- Will smaller CGRP-blocking molecules with central access prove more effective?
Common questions
If these drugs can't enter the brain, how do they stop migraines?
Are anti-CGRP antibodies better than older migraine preventives?
Read the original research
The locus of Action of CGRPergic Monoclonal Antibodies Against Migraine: Peripheral Over Central Mechanisms.
CNS & neurological disorders drug targets, 19(5), 344-359
Citation
González-Hernández, Abimael; Marichal-Cancino, Bruno A; García-Boll, Enrique; Villalón, Carlos M. (2020). The locus of Action of CGRPergic Monoclonal Antibodies Against Migraine: Peripheral Over Central Mechanisms.. CNS & neurological disorders drug targets, 19(5), 344-359. https://doi.org/10.2174/1871527319666200618144637